Products for Research Use Only

Nirogacestat (dihydrobromide)

CAT: 0804-HY-15185B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15185B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers[1].
CAS Number
1962925-29-6
Product Name Alternative
PF-3084014 (dihydrobromide) ; PF-03084014 (dihydrobromide)
UNSPSC
12352005
Target
Apoptosis; γ-secretase
Type
Reference compound
Related Pathways
Apoptosis; Neuronal Signaling; Stem Cell/Wnt
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nirogacestat-dihydrobromide.html
Purity
99.9
Solubility
DMSO : 80 mg/mL (ultrasonic)
Smiles
FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1.Br.Br
Molecular Formula
C27H43Br2F2N5O
Molecular Weight
651.47
References & Citations
[1]Wei P, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010 Jun;9 (6) :1618-28.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
BioRxiv. 2025 May 28.|ACS Appl Mater Interfaces. 2024 Sep 11;16 (36) :47075-47088.|Cancer Cell. 2021 Mar 8;39 (3) :380-393.e8.|EBioMedicine. 2025 Aug 15:119:105879.|EMBO Mol Med. 2017 Jul;9 (7) :950-966.|Int J Oncol. 2018 Jul;53 (1) :99-112.|J Biol Chem. 2019 Jul 19;294 (29) :11276-11285.|J Biol Chem. 2021 Jan-Jun:296:100593.|J Clin Invest. 2020 Feb 3;130 (2) :612-624.|Mol Immunol. 2018 Jul:99:191-198.|Nat Biotechnol. 2024 Nov 25.|Nat Mater. 2025 Feb 17.|Nat Med. 2023 Sep;29 (9) :2295-2306.|Neuron. 2023 Jun 21;111 (12) :1898-1913.e5.|Research Square Print. 2023 Mar 20.

Chemical Information

Nirogacestat Hydrobromide

Nirogacestat dihydrobromide is a hydrobromide salt obtained by reaction of nirogacestat with two equivalents of hydrobromic acid. It has a role as an antineoplastic agent and a gamma-secretase modulator. It contains a nirogacestat(2+).

CAS Number1962925-29-6
PubChem CID121513889
IUPAC Name(2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide;dihydrobromide
Molecular FormulaC27H43Br2F2N5O
Molecular Weight651.5
Topological Polar Surface Area71
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count6
Rotatable Bond Count11
Heavy Atom Count37
Formal Charge0
Complexity685
SMILES
CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F.Br.Br
InChI
InChI=1S/C27H41F2N5O.2BrH/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4;;/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35);2*1H/t20-,23-;;/m0../s1
InChIKey
LXEYYZYDWLAIPW-KBVFCZPLSA-N
Chemical Structure
2D Structure
2D structure of Nirogacestat Hydrobromide
CAS: 1962925-29-6
CID: 121513889
Formula: C27H43Br2F2N5O
MW: 651.5
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight651.5
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count6
Rotatable Bond Count11
Exact Mass651.17819
Monoisotopic Mass649.18024
Topological Polar Surface Area71 Ų
Heavy Atom Count37
Formal Charge0
Complexity685
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count3
Compound Is CanonicalizedYes